Researchreleasedby the MassachusettsInstituteof Technology describes an adhesive patch that can deliver a triple-combination of drug, gene, andlight-basedtherapy to colorectal tumors.
While the drug exhibited double-digit growth in the last couple of quarters due to its use in triple-combination therapy, patients are going off the therapy, and this should result in declining sales going forward.
However, a triple therapy combination of a diuretic with an ACE inhibitor or ARB and an NSAID was associated with a 31% higher rate of kidney injury, particularly elevated in the first 30 days of treatment during which it was 82% higher.